The Great American Recovery Initiative and the Department of Health and Human Services’ $100 million Safety Through Recovery, Engagement, and Evidence-based Treatment and Supports (STREETS) initiative have been introduced as the Trump administration’s next steps in addressing addiction and homelessness. These programs represent another step in the Trump administration’s mission to redefine how substance use is measured and addressed. That vision is becoming increasingly clear in the language used to describe what these initiatives will not support.
In announcing the STREETS program, the HHS under Secretary Robert F. Kennedy Jr. described harm reduction and housing-first approaches as “ineffective,” arguing that such programs enable drug use and undermine recovery. That framing represents a direct challenge to clinical models that have contributed to lower rates of addiction and homelessness for many years.
If these initiatives move forward as written, clinicians may soon need to confront a practical question: What does addiction care look like when harm reduction and housing-focused interventions are no longer treated as legitimate components of recovery?
Harm Reduction and Housing Are Embedded in Recovery-Oriented Care
The assertion that harm reduction is not evidence-based stands in contrast to decades of research demonstrating reduced mortality, reduced HIV and hepatitis C transmission, and increased treatment uptake in settings where harm reduction services are available.
The same principle applies to housing-first models. Research and real-world outcomes have consistently correlated stable housing with improved treatment retention, reduced emergency service utilization, and greater long-term stabilization among individuals with co-occurring substance use and mental health conditions.
The Clinical Realities of Harm Reduction
The administration’s recent messaging attempts to separate harm reduction from recovery, but in clinical practice the two are deeply intertwined. Recovery from substance use disorder is rarely linear. Patients relapse, cycle through readiness stages, or experience instability that makes immediate abstinence unrealistic.
That’s where harm reduction comes in. These strategies are a mechanism for keeping patients alive and engaged long enough to see their recovery journeys through. In that sense, harm reduction functions not as an alternative to recovery, but rather as a step towards achieving it. Decoupling harm reduction from recovery ignores the clinical reality that survival and engagement are prerequisites to sustained abstinence.
Progress toward recovery does not occur only in the absence of substance use. It can include reduced frequency of use, fewer overdoses, stable housing, consistent clinic engagement, and improved management of co-occurring conditions. Harm reduction strategies often facilitate those incremental gains.
A Federal Recalibration on Addiction Policy
Since taking power in January 2025, the Trump Administration has steadily moved federal messaging around addiction care away from explicit endorsement of harm reduction and housing-first models.
In July 2025, the administration issued the executive order Ending Crime and Disorder on America’s Streets, establishing a framework for its homelessness response. Among its provisions was a directive that SAMHSA ensure discretionary grants fund “evidence-based programs” and not support certain harm reduction or safe consumption initiatives, which it characterized as enablers of continued drug use. The order also moved away from federal endorsement of housing-first policies, directing the HHS to end support for such initiatives.
While framed as a push for accountability and measurable outcomes, the directive narrowed which interventions would qualify as federally supported. The rhetoric of recovery remains central to the Trump admin’s addiction policy narrative, but the range of strategies recognized as contributing to recovery has narrowed.
What Addiction Care Could Look Like Without Harm Reduction
With federal priorities moving toward a narrower definition of recovery that centers abstinence without supporting harm-reduction infrastructure, the continuum of care may become less stable. If harm reduction is phased out of federal grant criteria, programs that rely on grant funding for naloxone distribution, syringe access, or outreach could face funding uncertainty. Performance metrics may begin to prioritize drug-free status or program completion over mortality reduction, infectious disease prevention, and sustained engagement in care.
For nurse practitioners who care for patients with SUD, these possibilities are not abstract. Harm reduction often precedes treatment initiation. Housing stability often precedes consistent follow-up.
Ultimately, both the advocates and opponents of harm reduction agree that recovery is the end goal for treating substance use disorder. The real question is whether the tools that sustain patients long enough to reach it will remain part of the federal definition of effective care.
